Mifamurtide vs HBD-2
Head-to-head comparison of Mifamurtide (Muramyl Tripeptide Phosphatidylethanolamine) and HBD-2 (Human Beta-Defensin 2) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Mifamurtide | HBD-2 |
|---|---|---|
| Category | Immune Support | Immune Support |
| Full Name | Muramyl Tripeptide Phosphatidylethanolamine | Human Beta-Defensin 2 |
| Molecular Weight | N/A | 4316 Da |
| Half-Life | 2-4 h | Minutes to hours; protease-sensitive |
| Amino Acids | N/A | 41 |
| Typical Dose | 2 mg/m2 | Research use only; no approved human dose |
| Route | Intravenous | Topical / Intranasal / Research parenteral |
| Purity | ≥98% | ≥98% |
| Studies Count | 150 | 420 |
| Research Status | Clinical | Pre-clinical |
Mifamurtide Benefits
- ✓macrophage-activation
- ✓innate-immune-signaling
- ✓immune-adjuvant-research
- ✓cytokine-response
HBD-2 Benefits
- ✓broad-spectrum antimicrobial activity
- ✓epithelial barrier defense
- ✓innate immune modulation
- ✓anti-biofilm potential
Mifamurtide Dosing
2 mg/m2 IV|2x weekly for 12 weeks|then weekly for 24 weeks in approved regimens
HBD-2 Dosing
0.1–10 µM in vitro|1–5 mg/kg in animal models|No established human dose
Mifamurtide Side Effects
- ⚠fever/chills
- ⚠fatigue
- ⚠nausea
HBD-2 Side Effects
- ⚠local irritation at high concentrations
- ⚠proteolytic instability
- ⚠potential pro-inflammatory signaling
Research Overview
Mifamurtide
Mifamurtide has substantial literature as an innate immune activator and is an approved oncology adjunct in some regions. Research centers on NOD-like receptor signaling, macrophage activation, and downstream cytokine effects.
HBD-2
Human beta-defensin 2 has been studied extensively for direct microbicidal effects and for its role in shaping mucosal immunity. Preclinical work shows activity against Gram-negative and Gram-positive organisms, with additional effects on leukocyte recruitment and wound defense.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.